Rx Product News (April 2018)

Pharmacy Times, April 2018 Respiratory Health, Volume 84, Issue 4

Read about the Rx products featured in April.

Daiichi-Sankyo

INDICATION: MorphaBond ER (morphine sulfate extended-release) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

DOSAGE FORM: Extended-release tablets: 15, 30, 60, and 100 mg

FOR MORE INFORMATION: daiichisankyo.com

REBINYNMANUFACTURED BY: Novo Nordisk

INDICATION: Novo Nordisk said that Rebinyn Coagulation Factor IX (recombinant), GlycoPEGlated, has been made available to pharmacies. The FDA approved the drug in May 2017 for treating and controlling bleeding in adults and children.

DOSAGE FORM: Lyophilized powder for solution for intravenous injection

FOR MORE INFORMATION: rebinyn.com

ZYTIGAMANUFACTURED BY: Janssen Pharmaceutical Companies of Johnson & Johnson

INDICATION: The FDA has approved a new indication for abiraterone acetate (Zytiga, Janssen) in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer.

DOSAGE FORM: Film-coated tablet: 500 and 250 mg; uncoated tablet: 250 mg

FOR MORE INFORMATION: zytiga.com

QVAR REDIHALERMANUFACTURED BY: Teva Pharmaceutical Industries Ltd

INDICATION: Teva said that beclomethasone dipropionate HFA (QVAR RediHaler) Inhalation Aerosol is now commercially available to patients in both 40 and 80 mcg strengths by prescription in the United States. QVAR RediHaler is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients aged 4 years and older.

DOSAGE FORM: Breath-actuated inhalation aerosol: 40 or 80 mcg per actuation

FOR MORE INFORMATION: tevapharm.com